Literature DB >> 26864358

Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments.

Lori D McLeod1, Joseph C Cappelleri2, Ron D Hays3.   

Abstract

This article reviews methods used to facilitate the interpretation and evaluation of group-level differences in clinical outcome assessments. These methods complement and supplement tests of statistical significance. Examples, including studies in nutrition, are used to illustrate the application of the interpretation methods for group-level comparisons from experimental or observational studies. In addition, specific pitfalls of evaluating change in meta-analysis studies are described. A set of recommendations is provided. This review is intended as an introduction for the novice and as a refresher for the experienced researcher.
© 2016 American Society for Nutrition.

Keywords:  clinical outcome assessment; effect size; interpretation; minimally important difference; patient-reported outcome

Mesh：

Year:  2016        PMID： 26864358      PMCID： PMC4763495          DOI： 10.3945/ajcn.115.120378

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN： 0002-9165            Impact factor:   7.045


  51 in total

1.  The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?

Authors:  R D Hays; J M Woolley
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  Defining clinically meaningful change in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2003-05       Impact factor: 6.437

3.  Data extraction errors in meta-analyses that use standardized mean differences.

Authors:  Peter C Gøtzsche; Asbjørn Hróbjartsson; Katja Maric; Britta Tendal
Journal:  JAMA       Date:  2007-07-25       Impact factor: 56.272

4.  Using Effect Size-or Why the P Value Is Not Enough.

Authors:  Gail M Sullivan; Richard Feinn
Journal:  J Grad Med Educ       Date:  2012-09

5.  The new statistics: why and how.

Authors:  Geoff Cumming
Journal:  Psychol Sci       Date:  2013-11-12

Review 6.  A point of minimal important difference (MID): a critique of terminology and methods.

Authors:  Madeleine T King
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-04       Impact factor: 2.217

Review 7.  Interpreting patient-reported outcome results: US FDA guidance and emerging methods.

Authors:  Lori D McLeod; Cheryl D Coon; Susan A Martin; Sheri E Fehnel; Ron D Hays
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-04       Impact factor: 2.217

8.  School-based obesity treatment and prevention programs: all in all, just another brick in the wall?

Authors:  N Durant; M L Baskin; O Thomas; D B Allison
Journal:  Int J Obes (Lond)       Date:  2008-12       Impact factor: 5.095

9.  Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales.

Authors:  Brennan M R Spiegel; Ron D Hays; Roger Bolus; Gil Y Melmed; Lin Chang; Cynthia Whitman; Puja P Khanna; Sylvia H Paz; Tonya Hays; Steve Reise; Dinesh Khanna
Journal:  Am J Gastroenterol       Date:  2014-09-09       Impact factor: 10.864

10.  Evidence-based effect size estimation: an illustration using the case of acupuncture for cancer-related fatigue.

Authors:  Michael F Johnston; Ron D Hays; Ka-Kit Hui
Journal:  BMC Complement Altern Med       Date:  2009-01-13       Impact factor: 3.659
View more
  4 in total

1.  Does supplementation with leucine-enriched protein alone and in combination with fish-oil-derived n-3 PUFA affect muscle mass, strength, physical performance, and muscle protein synthesis in well-nourished older adults? A randomized, double-blind, placebo-controlled trial.

Authors:  Caoileann H Murphy; Ellen M Flanagan; Giuseppe De Vito; Davide Susta; Kathleen A J Mitchelson; Elena de Marco Castro; Joan M G Senden; Joy P B Goessens; Agnieszka Mikłosz; Adrian Chabowski; Ricardo Segurado; Clare A Corish; Sinead N McCarthy; Brendan Egan; Luc J C van Loon; Helen M Roche
Journal:  Am J Clin Nutr       Date:  2021-06-01       Impact factor: 7.045

2.  Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial.

Authors:  Bill Cavanagh; Paul J Gomes; Christopher E Starr; Kelly K Nichols; Todd C Brady
Journal:  Ophthalmol Ther       Date:  2022-05-18

3.  Camp-based family treatment of childhood obesity: randomised controlled trial.

Authors:  Beate Benestad; Samira Lekhal; Milada Cvancarova Småstuen; Jens Kristoffer Hertel; Vidar Halsteinli; Rønnaug Astri Ødegård; Jøran Hjelmesæth
Journal:  Arch Dis Child       Date:  2016-11-02       Impact factor: 3.791

4.  Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.

Authors:  Ruben A Mesa; Nicolaas Schaap; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Francesco Passamonti; Sonja Zweegman; Moshe Talpaz; Srdan Verstovsek; Shelonitda Rose; Pranav Abraham; Jennifer Lord-Bessen; Derek Tang; Shien Guo; Xiaomei Ye; Claire N Harrison
Journal:  Hemasphere       Date:  2021-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.